Christensen Jacob, Davidoski Filip Søskov, Skaarup Kristoffer Grundtvig, Lassen Mats Christian Højbjerg, Alhakak Alia Sead, Sengeløv Morten, Nielsen Anne Bjerg, Johansen Niklas Dyrby, Bundgaard Henning, Hassager Christian, Jabbari Reza, Carlsen Jørn, Kirk Ole, Kristiansen Ole Peter, Nielsen Olav Wendelboe, Ulrik Charlotte Suppli, Sivapalan Pradeesh, Gislason Gunnar, Iversen Kasper, Jensen Jens Ulrik Stæhr, Schou Morten, Hviid Anders, Krause Tyra Grove, Biering-Sørensen Tor
Department of Cardiology, Copenhagen University Hospital, Herlev and Gentofte, Copenhagen, Denmark.
Department of Cardiology, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark.
Cardiology. 2023;148(1):48-57. doi: 10.1159/000528308. Epub 2022 Dec 1.
COVID-19 has spread globally in waves, and Danish treatment guidelines have been updated following the first wave. We sought to investigate whether the prognostic values of echocardiographic parameters changed with updates in treatment guidelines and the emergence of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, 20E (EU1) and alpha (B.1.1.7), and further to compare cardiac parameters between patients from the first and second wave.
A total of 305 patients hospitalized with COVID-19 were prospectively included, 215 and 90 during the first and second wave, respectively. Treatment in the study was defined as treatment with remdesivir, dexamethasone, or both. Patients were assumed to be infected with the dominant SARS-CoV-2 variant at the time of their hospitalization.
Mean age for the first versus second wave was 68.7 ± 13.6 versus 69.7 ± 15.8 years, and 55% versus 62% were males. Left ventricular (LV) systolic and diastolic function was worse in patients hospitalized during the second wave (LV ejection fraction [LVEF] for first vs. second wave = 58.5 ± 8.1% vs. 52.4 ± 10.6%, p < 0.001; and global longitudinal strain [GLS] = 16.4 ± 4.3% vs. 14.2 ± 4.3%, p < 0.001). In univariable Cox regressions, reduced LVEF (hazard ratio [HR] = 1.07 per 1% decrease, p = 0.002), GLS (HR = 1.21 per 1% decrease, p < 0.001), and tricuspid annular plane systolic excursion (HR = 1.18 per 1 mm decrease, p < 0.001) were associated with COVID-related mortality, but only GLS remained significant in fully adjusted analysis (HR = 1.14, p = 0.02).
Reduced GLS was associated with COVID-related mortality independently of wave, treatment, and the SARS-CoV-2 variant. LV function was significantly impaired in patients hospitalized during the second wave.
新冠病毒病(COVID-19)已在全球呈多波传播,丹麦的治疗指南在第一波疫情后已更新。我们试图调查超声心动图参数的预后价值是否随治疗指南的更新以及新型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变异株20E(EU1)和α(B.1.1.7)的出现而改变,并进一步比较第一波和第二波患者的心脏参数。
前瞻性纳入了305例因COVID-19住院的患者,第一波和第二波分别为215例和90例。本研究中的治疗定义为使用瑞德西韦、地塞米松或两者联合治疗。假定患者在住院时感染的是当时占主导的SARS-CoV-2变异株。
第一波和第二波患者的平均年龄分别为68.7±13.6岁和69.7±15.8岁,男性比例分别为55%和62%。第二波住院患者的左心室(LV)收缩和舒张功能较差(第一波与第二波的左心室射血分数[LVEF]分别为58.5±8.1%和52.4±10.6%,p<0.001;整体纵向应变[GLS]分别为16.4±4.3%和14.2±4.3%,p<0.001)。在单变量Cox回归分析中,LVEF降低(每降低1%的风险比[HR]=1.07,p=0.002)、GLS降低(每降低1%的HR=1.21,p<0.001)和三尖瓣环平面收缩期位移降低(每降低1mm的HR=1.18,p<0.001)与COVID-19相关死亡率相关,但在完全调整分析中只有GLS仍具有显著性(HR=1.14,p=0.02)。
GLS降低与COVID-19相关死亡率独立相关,不受疫情波次、治疗和SARS-CoV-2变异株的影响。第二波住院患者的左心室功能显著受损。